Pharmacy Focus: Oncology Edition - PARP Inhibitors Are Changing the Game in Prostate Cancer

This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.

Interested in learning more? Check out this related content:

• FDA Approves New Combination Therapy for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
• Image-Guided Adaptive Radiation Treatments May Reduce Short-Term Adverse Effects in Patients With Prostate Cancer Compared to Non-Adaptive Treatments
• Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer